Australia - engleză - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 1.1 g; glucose, quantity: 50 g - injection, solution - excipient ingredients: water for injections - sodium chloride (%) and glucose (%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium and chloride ion concentrations, it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn486 - these solutions are indicated for parenteral replacement of extracellular losses of fluid and electrolytes, with or without minimal carbohydrate calories, as required by the clinical condition of the patient. solutions containing lactate are not for use in the treatment of lactic acidosis. to open: tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication prepare additive port. using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. the additive port may be protected by covering with an additive cap. mix container contents thoroughly

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

carelide - sodium chloride; calcium chloride dihydrate; potassium chloride; sodium lactate solution 60% - solution for infusion - solutions affecting the electrolyte balance; electrolytes

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

laboratoire aguettant - sodium chloride; calcium chloride dihydrate; potassium chloride; sodium lactate solution 60% - solution for infusion - solutions affecting the electrolyte balance; electrolytes

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hospira, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 1 ml - 23.4% sodium chloride injection, usp is indicated for use as an electrolyte replenisher in parenteral fluid therapy. it serves as an additive for total parenteral nutrition (tpn) and as an additive for carbohydrate containing i.v. fluids. 23.4% sodium chloride injection, usp additive solution is contraindicated in patients with hypernatremia or fluid retention.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - phenytoin sodium, quantity: 100 mg - injection, solution - excipient ingredients: propylene glycol; sodium hydroxide; ethanol; water for injections - control of status epilepticus, tonic-clonic (grand mal), psychomotor seizures and the prevention of seizures occuring during or following neurosurgery. phenytoin will prevent or effectively decrease the incidence and severity of convulvsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, phenytoin frequently improves the mental condition and outlook of epileptic patients. it has also been used in the treatment of certain cardiac arrhythmias, particularly in those patients who do not respond to convential antiarrhythmic agents or to cardioversion. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administation).

Australia - engleză - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - phenytoin sodium, quantity: 250 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; ethanol; propylene glycol - control of status epilepticus, tonic-clonic (grand mal), psychomotor seizures and the prevention of seizures occuring during or following neurosurgery. phenytoin will prevent or effectively decrease the incidence and severity of convulvsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, phenytoin frequently improves the mental condition and outlook of epileptic patients. it has also been used in the treatment of certain cardiac arrhythmias, particularly in those patients who do not respond to convential antiarrhythmic agents or to cardioversion. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administation).

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - sodium chloride potassium chloride calcium chloride dihydrate sodium lactate glucose monohydrate - solution for infusion - %v/v

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - sodium chloride sodium lactate potassium chloride calcium chloride dihydrate - solution for infusion - 1

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer (nsclc),pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology.,pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology after prior platinum-based chemotherapy.